ChipCare is addressing the women’s health & sexually transmitted infection (STI) markets and is currently developing the PAx2 platform with multiplexed Chlamydia / Gonorrhea / Trichomoniasis (CT/NG/TV) nucleic acid test and an HIV/Syphilis immunoassay.  The PAx has the unique capability to rapidly perform multiple key assay classes including nucleic acid, immunoassay and cell surface marker tests using disposable cartridges on the same analyzer, thereby improving patient outcomes as well as augmenting health system efficiencies and reducing cost.